Ono Pharma licenses Biohaven IgG degrader portfolio for Japan, South Korea, Taiwan, ASEAN in deal worth up to USD 100 million
PUBT · 2d ago
Share
Listen to the news
- ONO Pharma signed an exclusive license with Biohaven to develop, register, and sell IgG degrader drugs across Japan, South Korea, Taiwan, and ASEAN.
- Deal covers Biohaven’s MoDE-based IgG degrader portfolio, led by BHV-1300, now in global Phase 3 trials for Graves’ disease.
- Biohaven to receive USD 80 million upfront, USD 20 million in milestones, and about 20% royalties on net sales.
- ONO Pharma expects a minor impact on consolidated results for the fiscal year ending March 31, 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending